Progression of lupus-like disease drives the appearance of complement-activating IgG antibodies in MRL/lpr mice

Rheumatology

Volumn 49, Issue 12, 2010, Pages 2273-2280

  Papp, Krisztián ^a   Végh, Péter ^a   Tchorbanov, Andrey ^b   Vassilev, Tchavdar ^b   Erdei, Anna ^a   Prechl, József ^a  

^a EÖTVÖS LORÁND UNIVERSITY   (Hungary)

^b INSTITUTE OF MICROBIOLOGY   (Bulgaria)

Author keywords

Anti DNA antibody; Autoantibody; Complement activation; Complement C3 component; Lupus

Indexed keywords

ANTINUCLEAR ANTIBODY; COMPLEMENT COMPONENT C3; DOUBLE STRANDED DNA; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; NUCLEIC ACID; PLASMID DNA; POLYCLONAL ANTIBODY; RNA; SINGLE STRANDED DNA;

ANIMAL EXPERIMENT; ANTIGEN BINDING; ARTICLE; COMPLEMENT ACTIVATION; DISEASE COURSE; LUPUS LIKE SYNDROME; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN LOCALIZATION;

EID: 78549248517     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keq278     Document Type: Article

References (41)

1. Krysko DV, D'Herde K, Vandenabeele P. Clearance of apoptotic and necrotic cells and its immunological consequences. Apoptosis 2006;11:1709-26.
2. Hicks PS, Saunero-Nava L, Du Clos TW, Mold C. Serum amyloid P component binds to histones and activates the classical complement pathway. J Immunol 1992;149: 3689-94.
3. Palaniyar N, Nadesalingam J, Clark H, Shih MJ, Dodds AW, Reid KB. Nucleic acid is a novel ligand for innate, immune pattern recognition collectins surfactant proteins A and D and mannose-binding lectin. J Biol Chem 2004;279:32728-36.
4. Taylor PR, Carugati A, Fadok VA et al. A hierarchical role for classical pathway complement proteins in the clearance of apoptotic cells in vivo. J Exp Med 2000;192: 359-66.
5. Nauta AJ, Trouw LA, Daha MR et al. Direct binding of C1q to apoptotic cells and cell blebs induces complement activation. Eur J Immunol 2002;32:1726-36.
6. Kuraya M, Ming Z, Liu X, Matsushita M, Fujita T. Specific binding of L-ficolin and H-ficolin to apoptotic cells leads to complement activation. Immunobiology 2005;209:689-97.
7. Du Clos TW. The interaction of C-reactive protein and serum amyloid P component with nuclear antigens. Mol Biol Rep 1996;23:253-60.
8. Xu W, Berger SP, Trouw LA et al. Properdin binds to late apoptotic and necrotic cells independently of C3b and regulates alternative pathway complement activation. J Immunol 2008;180:7613-21.
9. Trouw LA, Bengtsson AA, Gelderman KA, Dahlback B, Sturfelt G, Blom AM. C4b-binding protein and factor H compensate for the loss of membrane-bound complement inhibitors to protect apoptotic cells against excessive complement attack. J Biol Chem 2007;282:28540-8.
10. Krysko DV, D'Herde K, Vandenabeele P. Clearance of apoptotic and necrotic cells and its immunological consequences. Apoptosis 2006;11:1709-26.
11. Trouw LA, Bengtsson AA, Gelderman KA, Dahlback B, Sturfelt G, Blom AM. C4b-binding protein and factor H compensate for the loss of membrane-bound complement inhibitors to protect apoptotic cells against excessive complement attack. J Biol Chem 2007;282:28540-8.
12. Nauta AJ, Raaschou-Jensen N, Roos A et al. Mannose-binding lectin engagement with late apoptotic and necrotic cells. Eur J Immunol 2003;33:2853-63.
13. Gershov D, Kim S, Brot N, Elkon KB. C-reactive protein binds to apoptotic cells, protects the cells from assembly of the terminal complement components, and sustains an antiinflammatory innate immune response: implications for systemic autoimmunity. J Exp Med 2000;192:1353-64.
14. Gaipl US, Kuenkele S, Voll RE et al. Complement binding is an early feature of necrotic and a rather late event during apoptotic cell death. Cell Death Differ 2001;8:327-34.
15. Erwig LP, Henson PM. Immunological consequences of apoptotic cell phagocytosis. Am J Pathol 2007;171:2-8.
16. Behrendt M, Partridge LJ, Griffiths B, Goodfield M, Snaith M, Lindsey NJ. The role of somatic mutation in determining the affinity of anti-DNA antibodies. Clin Exp Immunol 2003;131:182-9.
17. Wellmann U, Letz M, Herrmann M, Angermuller S, Kalden JR, Winkler TH. The evolution of human anti-double-stranded DNA autoantibodies. Proc Natl Acad Sci USA 2005;102:9258-63.
18. Yung S, Chan TM. Anti-DNA antibodies in the pathogenesis of lupus nephritis-the emerging mechanisms. Autoimmun Rev 2008;7:317-21.
19. Rothfield NF, Stollar BD. The relation of immunoglobulin class, pattern of anti-nuclear antibody, and complement-fixing antibodies to DNA in sera from patients with systemic lupus erythematosus. J Clin Invest 1967;46:1785-94.
20. Mackworth-Young CG, Chan JK, Bunn CC, Hughes GR, Gharavi AE. Complement fixation by anti-dsDNA antibodies in SLE: measurement by radioimmunoassay and relationship with disease activity. Ann Rheum Dis 1986;45:314-8.
21. Valle RR, Eaton RB, Schnneider G, Schur PH. Complement activation by antibodies to DNA in systemic lupus erythematosus measured by enzyme immunoassay. Clin Immunol Immunopathol 1985;34:345-54.
22. Beaulieu A, Quismorio FP Jr, Friou GJ, Vayuvegula B, Mirick G. IgG antibodies to double-stranded DNA in systemic lupus erythematosus sera. Independent variation of complement fixing activity and total antibody content. Arthritis Rheum 1979;22:565-70.
23. Lamers MC, De Groot ER, Daha MR, Roos D. Influence of complement components on the size and the opsonization of DNA-anti-DNA complexes. Scand J Immunol 1982;16: 389-401.
24. Esparza RH, Swaak T, Aarden L, Smeenk R. Complement-fixing antibodies to dsDNA detected by the immunofluorescence technique on Crithidia luciliae. A critical appraisal. J Rheumatol 1985;12:1109-17.
25. Papp K, Szekeres Z, Terenyi N, Isaak A, Erdei A, Prechl J. On-chip complement activation adds an extra dimension to antigen microarrays. Mol Cell Proteomics 2007;6: 133-40.
26. Tchorbanov AI, Voynova EN, Mihaylova NM et al. Selective silencing of DNA-specific B lymphocytes delays lupus activity in MRL/lpr mice. Eur J Immunol 2007;37: 3587-96.
27. Voynova EN, Tchorbanov AI, Todorov TA, Vassilev TL. Breaking of tolerance to native DNA in nonautoimmune mice by immunization with natural protein/DNA complexes. Lupus 2005;14:543-50.
28. Papp K, Szekeres Z, Erdei A, Prechl J. Two-dimensional immune profiles improve antigen microarray-based characterization of humoral immunity. Proteomics 2008;8: 2840-8.
29. Taylor PR, Carugati A, Fadok VA et al. A hierarchical role for classical pathway complement proteins in the clearance of apoptotic cells in vivo. J Exp Med 2000;192: 359-66.
30. Jiang H, Cooper B, Robey FA, Gewurz H. DNA binds and activates complement via residues 14-26 of the human C1q A chain. J Biol Chem 1992;267: 25597-601.
31. Trouw LA, Nilsson SC, Goncalves I, Landberg G, Blom AM. C4b-binding protein binds to necrotic cells and DNA, limiting DNA release and inhibiting complement activation. J Exp Med 2005;201:1937-48.
32. Sekine H, Reilly CM, Molano ID et al. Complement component C3 is not required for full expression of immune complex glomerulonephritis in MRL/lpr mice. J Immunol 2001;166:6444-51.
33. Sheerin NS, Abe K, Risley P, Sacks SH. Accumulation of immune complexes in glomerular disease is independent of locally synthesized c3. J Am Soc Nephrol 2006;17: 686-96.
34. Moll T, Nitschke L, Carroll M, Ravetch JV, Izui S. A critical role for Fc gamma RIIB in the induction of rheumatoid factors. J Immunol 2004;173:4724-8.
35. Radic M, Marion T, Monestier M. Nucleosomes are exposed at the cell surface in apoptosis. J Immunol 2004; 172:6692-700.
36. Yung S, Chan TM. Anti-DNA antibodies in the pathogenesis of lupus nephritis-the emerging mechanisms. Autoimmun Rev 2008;7:317-21.
37. Kalaaji M, Mortensen E, Jorgensen L, Olsen R, Rekvig OP. Nephritogenic lupus antibodies recognize glomerular basement membrane-associated chromatin fragments released from apoptotic intraglomerular cells. Am J Pathol 2006;168:1779-92.
38. Behrendt M, Partridge LJ, Griffiths B, Goodfield M, Snaith M, Lindsey NJ. The role of somatic mutation in determining the affinity of anti-DNA antibodies. Clin Exp Immunol 2003;131:182-9.
39. Wellmann U, Letz M, Herrmann M, Angermuller S, Kalden JR, Winkler TH. The evolution of human anti-double-stranded DNA autoantibodies. Proc Natl Acad Sci USA 2005;102:9258-63.
40. Lutz HU, Fumia S, Schurtenberger C, Alaia V. Opinion paper: stimulation of complement amplification or activation of the alternative pathway of complement? Mol Immunol 2007;44:3862-5.
41. Papp K, Vegh P, Miklos K et al. Detection of complement activation on antigen microarrays generates functional antibody profiles and helps characterization of disease-associated changes of the antibody repertoire. J Immunol 2008;181:8162-9.